Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development ...

Eleva, a German biopharmaceutical company, and 3PBIOVIAN, a global contract development and manufacturing organization (CDMO) ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

For children with nephrotic syndrome, there was no difference in time to relapse between two commonly used non-steroid ...

Analysts at William Blair upped their FY2024 earnings estimates for Apellis Pharmaceuticals in a report issued on Tuesday, January 21st. William Blair analyst L. Hanbury-Brown now forecasts that the ...

Karen Lewis (JO:LEWJ), the Chief People Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.75 billion market cap biotech company, recently sold 1,241 shares of common stock. The shares were ...

The company investigates its lead drug candidate, PulmoStem. Amniotics investigates CogniStem against spinal muscular atrophy in children; CutiStem therapy for epidermolysis bullosa, burns and wound ...

AROC-3 is under development for the treatment of adult patients with complement-mediated renal disease (C3 glomerulopathy [C3G] (glomerulonephritis) and IgA nephropathy [IgAN]). It acts by targeting ...